Cancer Genetics Inc. (NASDAQ:CGIX)’s share price was down 4.4% during trading on Tuesday . The stock traded as low as $2.11 and last traded at $2.16, with a volume of 65,414 shares trading hands. The stock had previously closed at $2.26.

Separately, Zacks Investment Research upgraded shares of Cancer Genetics from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Thursday, July 28th.

The stock has a 50 day moving average price of $2.14 and a 200 day moving average price of $2.31. The stock’s market cap is $34.82 million.

Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.05. The firm had revenue of $7 million for the quarter, compared to analysts’ expectations of $6.50 million. During the same period in the prior year, the firm earned ($0.51) earnings per share. Cancer Genetics’s revenue was up 67.3% compared to the same quarter last year. Analysts predict that Cancer Genetics Inc. will post ($1.19) EPS for the current fiscal year.

In other news, Director John Pappajohn acquired 45,000 shares of the business’s stock in a transaction on Tuesday, August 16th. The shares were purchased at an average cost of $2.29 per share, with a total value of $103,050.00. Following the acquisition, the director now directly owns 2,287,109 shares of the company’s stock, valued at $5,237,479.61. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.